Highlights from ILCS24 by Stephen V Liu

The 6th International Lung Cancer Summit took place as a hybrid event in Lausanne, Switzerland, and online on October 4, 2024, at 10 AM CET.

The summit showcased the latest breakthroughs and developments in lung cancer treatment, featuring insights from leading global experts in thoracic oncology.

Utilizing digital platforms, the conference facilitated meaningful engagement and networking among attendees from medical offices, universities, and research institutes, allowing them to connect with esteemed medical oncologists and industry professionals.

Distinguished speakers from the USA, Spain, UK, Italy, Netherlands, France, Austria, and Switzerland contributed to the rich exchange of knowledge and innovation in lung cancer treatment and research.

Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared his insights on social media.

Discussing the evolving landscape of lung cancer

“In Lausanne and Geneva, Switzerland for ILCS24 to discuss the evolving landscape of lung cancer. Thanks to chairs Alfredo Addeo, Solange Peters for the invitation and for running such a rich meeting. Always grateful to see such great friends and brainstorm new strategies together.”

Sandip Patel at ILCS24 debating the stance of indefinite immunotherapy

“Sandip Patel at ILCS24 debating the stance of indefinite immunotherapy. Notes that 2 years of therapy is arbirtrary and in the event of relapse after stopping therapy, only 1/3 will respond again. Better approach is biomarker driven duration i.e. MRD.”

Giannis Mountzios debating for finite course of immunotherapy for NSCLC

“Giannis Mountzios debating for finite course of immunotherapy for NSCLC at ILCS24. No clear diff in target occupancy over time. Late recurrence off therapy occurs, but does indefinite therapy prevent that? Await ongoing studies such as DIAL to see if stop-and-go approach better.”

Perioperative IO for NSCLC

“Jordi Remon discusses perioperative IO for NSCLC at ILCS24. Inconsistent results with adjuvant immunotherapy. Benefit with atezolizumab strongest in the PD-L1 high subgroup. Perioperative and neoadjuvant have impressive results – how critical is the adjuvant component?”

Surgical dilemmas in the immunotherapy era

“Nuria Novoa at ILCS24 discusses surgical dilemmas in the immunotherapy era, stressing the importance of quality resection – which may include pneumonectomy.”

Overview of SCLC at ILCS24

“Overview of SCLC at ILCS24 from Solange Peters, Christian Grohe, and Patrizia Frosch. Progress in the past had been very slow but new drugs approved and some exciting studies ongoing with the hope of further changing standard of care.”

Insights on antibody drug conjugates (ADCs)

“Insights on antibody drug conjugates (ADCs) from the brilliant Jarushka Naidoo. Differences between compounds stemsfrom unique design and key questions will guide how we use these agents. Impressed with CNS efficacy. Eager to see novel combinations and agents!”

For more posts like this, visit oncodaily.com